Bioness StimRouter Neuromodulation System Acquires Coverage from Aetna

The leading provider of cutting edge, Bioness Inc., clinically supported rehabilitation therapies, is glad to announce that its StimRouter Neuromodulation System has got Aetna coverage effective March 8, 2017. Due to this coverage decision, Aetna considers the StimRouter medically essential durable medical equipment (DME) for members with intractable neurogenic pain, also termed as chronic pain of a peripheral nerve origin which the StimRouter is FDA cleared to treat.

Intractable neurogenic pain isn’t relieved by traditional medical techniques and highly treated with opioids as it has been identified by sufferers as an extreme and constant pain. The StimRouter Neuromodulation System decreases pain by targeting the affected peripheral nerve and is a cost-effective and long-term alternative to injections, immobilization, and prescription opioids. Aetna is the 3rd largest private insurer that is consisting of 23 million members in the USA and its decision to give coverage of the StimRouter Neuromodulation System opens the door to a latest treatment choice for those people that are suffering from chronic peripheral nerve pain.

“Payers seek at the long-term affect and cost effectiveness of devices closely when evaluating whether or not to extend coverage to members. Up until now sufferers suffering from intractable neurogenic pain have had restricted treatment options and mostly had to pay for care that is believed to be experimental out of pocket,” stated Todd Cushman, President and CEO of Bioness. “We’re very happy that Aetna has identified the worth that the StimRouter and other peripherally implanted nerve stimulation systems bring to their members. Gaining coverage from payers has always been part of the StimRouter strategy and we consider this will support our attempts in attaining coverage from insurers.”

Under the new policy of Aetna, the StimRouter is considered medically important when members meet particular criteria.

StimRouter was the 1st FDA cleared, minimally invasive, long-term, neuromodulation medical device demonstrated to treat chronic pain of a peripheral nerve origin. The StimRouter System acquired CE mark in the February of 2014 and the patient-controlled medical device is an adjunct to other modes of therapy, and is being well received by sufferers and clinicians alike.

For further information on the StimRouter Neuromodulation System, please do visit www.stimrouter.com.